Sangamo Therapeutics Inc
(LTS:0R1D)
$
2.18
-0.06 (-2.68%)
Market Cap: 492.41 Mil
Enterprise Value: 480.93 Mil
PE Ratio: 0
PB Ratio: 12.55
GF Score: 41/100 Sangamo Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021 / 05:15PM GMT
Release Date Price:
$10.13
Aspen Mori
BofA Securities, Research Division - Associate
All right. Good morning, and welcome to day 4 of the BofA Virtual Vegas Health Care Conference. My name is Aspen Mori. I'm an associate on the large cap biopharma team at BofA. I'm joined by senior biopharma analyst, Geoff Meacham. And we're lucky today to be speaking to Sangamo's CEO, Sandy Macrae. Sandy, how are you doing today?
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
I'm doing very well. A pleasure to be here.
Questions & Answers
Aspen Mori
BofA Securities, Research Division - Associate
Great. So I think what we'll start off is maybe we can kick off at a high level, how Sangamo's -- how everything is going over at Sangamo? How the business is operating in the middle of the -- or I guess, coming out to the extent of the pandemic? And then we can talk about some of your programs.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot